Cellares and GenomeFrontier Partner to Automate Virus-Free CAR-T Production
The collaboration will test whether Cellares' automated Cell Shuttle platform can efficiently manufacture virus-free CAR-T therapies.
Cellares, a contract developer and manufacturer, has announced a partnership with Taiwan-based GenomeFrontier Therapeutics to explore the use of its automated Cell Shuttle platform for producing virus-free CAR-T therapies. The evaluation will focus on whether the integrated system can handle the specific requirements of virus-free manufacturing, which avoids the use of viral vectors for gene delivery.
GenomeFrontier's approach to CAR-Ts relies on non-viral methods, potentially offering safety and cost advantages over traditional viral-based production. By combining this with Cellares' automation, the companies hope to demonstrate a more scalable and reproducible manufacturing process.
This is a single-source announcement, so no independent verification or contrasting views are available. The outcome of the evaluation could inform future adoption of automated platforms for virus-free cell therapies, but no timeline or specific success metrics were disclosed in the source.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.